The Liver Meeting 2021-NAFLD Debrief

Video Transcription

Video Summary

Dr. Manal Abdel-Malik presented a detailed debrief on Non-Alcoholic Fatty Liver Disease (NAFLD) research updates from the 2021 AASLD Symposium. She highlighted studies on various therapeutic interventions including FGF19 analogs, pegbelfermin, and combination therapies for NAFLD and NASH. The results showed some improvements in liver histology and biomarkers, but did not meet primary endpoints for fibrosis improvement. Additional research focused on lifestyle interventions, dietary influences, genetic factors, and non-invasive markers for predicting outcomes in NAFLD. Disparities in NAFLD outcomes based on race were also discussed, pointing out differences in disease progression and access to care. Dr. Abdel-Malik emphasized the importance of research collaboration, patient engagement, and the need to address disparities to advance NAFLD management and treatment.

Keywords

Non-Alcoholic Fatty Liver Disease

NAFLD

AASLD Symposium

FGF19 analogs

pegbelfermin

NASH

lifestyle interventions